MedTrace Logo

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

NCT01102231 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2021-02-16

Study results available
· View outcomes & findings →

Summary

Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy.

Conditions

  • Stage III Non-small Cell Lung Cancer

Interventions

DRUG

Chemotherapy

Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)

DRUG

ERBITUX

The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes

RADIATION

Radiotherapy

66 Gy (2 Gy by fraction, 5 fractions by week)

Sponsors & Collaborators

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Jean Trédaniel, MD, PhD · IFCT, GH Paris Saint-Joseph

  • Françoise Mornex, MD, PhD · IFCT, HCL Lyon-Sud

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2014-01-31
Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01102231 on ClinicalTrials.gov